Cargando…

Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis

BACKGROUND: Periprocedural heparin bridging therapy aims to reduce the risk of thromboembolic events in patients requiring an interruption in their anticoagulation therapy for the purpose of an elective procedure. The efficacy and safety of heparin bridging therapy has not been well established. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yong, Jing Wen, Yang, Li Xia, Ohene, Bright Eric, Zhou, Yu Jie, Wang, Zhi Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729256/ https://www.ncbi.nlm.nih.gov/pubmed/29237411 http://dx.doi.org/10.1186/s12872-017-0719-7

Ejemplares similares

Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta‐analysis
por: Kuo, Hsien‐Cheng, et al.
Publicado: (2020)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory Tests
por: Lessire, Sarah, et al.
Publicado: (2016)

Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures
por: Finks, Shannon W., et al.
Publicado: (2018)

Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
por: Maraj, Ilir, et al.
Publicado: (2018)

Outcomes of uninterrupted vs interrupted Periprocedural direct oral Anticoagulants in atrial Fibrillation ablation: A meta‐analysis
por: Basu‐Ray, Indranill, et al.
Publicado: (2021)

Severe Enoral Bleeding with a Direct Oral Anticoagulant after Tooth Extraction and Heparin Bridging Treatment
por: Ehrhard, Simone, et al.
Publicado: (2019)

Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry
por: Ferrandis, Raquel, et al.
Publicado: (2020)

Considerations Regarding the Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation
por: Reiffel, James A.
Publicado: (2018)

Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial
por: Zilberszac, Robert, et al.
Publicado: (2019)

Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation
por: van Vugt, S. P. G., et al.
Publicado: (2018)

Optimal Anticoagulant Strategy for Periprocedural Management of Atrial Fibrillation Ablation: A Systematic Review and Network Meta-Analysis
por: Kino, Tabito, et al.
Publicado: (2022)

Uptake and Utilization of the Management of Anticoagulation in the Periprocedural Period App: Longitudinal Analysis
por: Spyropoulos, Alex C, et al.
Publicado: (2018)

Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment
por: Zhang, Rong-feng, et al.
Publicado: (2021)

Relevance of Non-Bridging Therapy with Heparin during Temporary Interruption of Direct Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism
por: Oyakawa, Takuya, et al.
Publicado: (2022)

Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants
por: Yamaji, Hirosuke, et al.
Publicado: (2016)

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants
por: Brinkmeier-Theofanopoulou, Maria, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis
por: Tian, Yong, et al.
Publicado: (2023)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess?
por: Chandiramani, Rishi, et al.
Publicado: (2020)

Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Periprocedural Intravenous Heparin During Endovascular Treatment for Ischemic Stroke: Results From the MR CLEAN Registry
por: van de Graaf, Rob A., et al.
Publicado: (2019)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
por: Murakawa, Yuji, et al.
Publicado: (2017)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021)

Heparin bridge is associated with more post-polypectomy bleeding and emergency department visits among anticoagulated patients
por: Rebello, Dionne, et al.
Publicado: (2020)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Coagulation and heparin requirements during ablation in patients under oral anticoagulant drugs
por: Maury, Philippe, et al.
Publicado: (2020)

Safety of ECT in patients receiving an oral anticoagulant
por: Centanni, Nicolette R., et al.
Publicado: (2021)

Engineered heparins as new anticoagulant drugs
por: Vaidyanathan, Deepika, et al.
Publicado: (2016)

Non-Anticoagulant Heparins as Heparanase Inhibitors
por: Cassinelli, Giuseppe, et al.
Publicado: (2020)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Implementation of the Management of Anticoagulation in the Periprocedural Period App Into an Electronic Health Record: A Prospective Cohort Study
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Implementation of the Management of Anticoagulation in the Periprocedural Period App into an Electronic Health Record: A Cost-Effectiveness Analysis
por: Wang, Jason J., et al.
Publicado: (2023)

Regional Citrate Anticoagulation or Heparin Anticoagulation for Renal Replacement Therapy in Patients With Liver Failure: A Systematic Review and Meta-Analysis
por: Qi, Wenqian, et al.
Publicado: (2023)

Comparative Efficacy of Direct Oral Anticoagulants and Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism: A Systematic Review and Meta-Analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Impact of INR monitoring, reversal agent use, heparin bridging, and anticoagulant interruption on rebleeding and thromboembolism in acute gastrointestinal bleeding
por: Nagata, Naoyoshi, et al.
Publicado: (2017)

Evaluation of bleeding in patients receiving direct oral anticoagulants
por: Hellenbart, Erika L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a4sfi5rcjcoiijvmt3jbgmurom